BPC-157 for Health & Longevity
Evidence Review created on 09/30/2026 using AI4L + evidence-mcp / Sonnet 5.5
Also known as: Body Protection Compound-157, Body Protective Compound-157, BPC 157, BPC157, Bepecin, PL 14736, PL-10, PLD-116, Pentadecapeptide BPC 157, Gastric Pentadecapeptide BPC 157
Motivation
BPC-157 (Body Protection Compound-157) is a laboratory-made chain of 15 amino acids. Its sequence matches a fragment of a protein reported in human stomach fluid. It is sold online and offered by some clinics for tendon and joint injuries, digestive complaints and general healthy aging, and it has become one of the most discussed injectable substances among people who optimize their health.
Research began in Croatia in the early 1990s, and most published work comes from a few laboratories using rats and mice. Human research so far consists of a handful of small clinic-based reports. Drug regulators, anti-doping authorities and an advisory committee of the United States government have all taken positions on it in recent years, most recently in July 2026.
This review examines BPC-157 for health and longevity. It sets out the proposed biology, the reported benefits and risks, interactions, how it has been used, product quality, legal status, monitoring and ongoing research, and it weighs animal, human and regulatory sources by their strength.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
Selected expert commentary and narrative reviews that discuss BPC-157 in depth.
-
#403 ‒ Peptides: separating scientific promise from marketing hype - Peter Attia
Uses BPC-157 as the worked example in a framework for judging peptides (short chains of amino acids): unclear origin, mechanism, absent human evidence and unknown risks.
-
Benefits & Risks of Peptide Therapeutics for Physical & Mental Health - Andrew Huberman
A 20-minute segment covers BPC-157’s proposed blood-vessel and fibroblast (connective-tissue cell) effects, typical injection schedules, cycling (planned on-and-off periods) and tumor-growth concerns, stressing that human data are almost absent.
-
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing - McGuire et al., 2025
Reviews BPC-157 mechanisms, animal evidence and the three published human pilot studies (small preliminary studies) for tendon and joint healing, concluding it remains investigational.
-
Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review - Józwiak et al., 2025
Review of BPC-157’s biological activities, proposed mechanisms, probable toxicity and patents, written by authors outside the Zagreb group that discovered it.
-
BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers - Mateescu et al., 2026
Narrative review of pharmacokinetics (how the body absorbs and clears a drug) and formulation, highlighting a short half-life (time for drug levels to halve) set against long-lasting reported effects.
Note: No qualifying content was found for the other priority sources. Rhonda Patrick addresses BPC-157 only as one question within a members-only Q&A whose show notes are paywalled. Chris Kresser’s site returns only a 2019 podcast interview listing. Life Extension Magazine has no BPC-157 article. Lifespan.io’s only result is a 2025 news report on injection emergencies at a longevity conference, in which BPC-157 is one listed product rather than the subject.
Grokipedia
AI-generated encyclopedia entry covering structure, animal findings, small human reports, the 2026 advisory vote and anti-doping status; a secondary compilation whose citations are not independently appraised.
Examine
Summarizes BPC-157 as showing high efficacy in rats but little human evidence, with a rat-derived oral dose estimate and a safety database noting the anti-doping prohibition.
ConsumerLab
Are Peptides Such as BPC-157 and TB-500 Safe and Effective?
Independent testing organization states neither BPC-157 nor TB-500 (a synthetic thymosin beta-4 fragment) can legally be sold as a dietary supplement in the US or Canada; details are members-only.
Systematic Reviews
This section lists the only systematic review (a structured, predefined search and appraisal of all published studies) found; no meta-analysis (statistical pooling of study results) exists.
-
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review - Vasireddi et al., 2025
Found 36 studies (35 preclinical, meaning animal or laboratory, and one clinical); reported no clinical safety data and possible harm from contamination.
No meta-analysis exists, and no systematic review addresses risk on its own; the listed review covers both the claimed effect and safety. Scoping and narrative reviews were excluded.
Mechanism of Action
BPC-157 is a peptide, a chain of 15 amino acids. According to Attia, its proposed parent protein in gastric juice was never fully characterized and no principal receptor has been identified. Laboratory work links it to VEGFR2 (the receptor for vascular endothelial growth factor, VEGF, a signal driving new blood vessel growth, called angiogenesis), to endothelial nitric oxide synthase (eNOS, the vessel-wall enzyme producing nitric oxide, a vessel-relaxing gas), and to higher growth hormone receptor levels in tendon fibroblasts. Most animal work comes from the Zagreb group that discovered the compound and developed it commercially with the company Pliva, a potential financial interest.
Competing readings exist. The discovering group argues BPC-157 restores balance in blood-vessel growth and nitric oxide signaling; independent reviewers argue these pro-growth signals could be harmful. Both positions rest on non-human data.
Pharmacology: a 2026 review reports a plasma half-life (time for blood concentration to halve) under 30 minutes in two animal species and muscle-injection bioavailability (fraction reaching circulation) of 14–51%. A systematic review reports liver metabolism and kidney clearance. It resists stomach acid, and oral activity is reported in animals. Tissue distribution, selectivity and metabolizing enzymes (such as CYP enzymes, the liver’s main drug-processing family) remain uncharacterized in humans; only a two-person pilot from a clinic that administers the peptide, a potential financial interest, exists. Effects last far longer than the half-life, unexplained.
Historical Context & Evolution
According to USADA (the US Anti-Doping Agency), researchers examining stomach juice for a protective agent found an acid-stable peptide and named it “body protection compound”. The original intended use was gastrointestinal protection: a rat ligament study describes the compound, coded PL 14736, as an anti-ulcer peptide effective in inflammatory bowel disease (chronic bowel inflammation) therapy, though USADA, which earns nothing from BPC-157 sales, notes the bowel-disease studies appear to have been stopped without published conclusions.
Rat studies then reported faster Achilles tendon and ligament healing, and independent groups later reported blood-vessel signaling. Adoption for health optimization followed injury-recovery anecdotes, social media and a clinic case series (a report on patients treated without a comparison group) from a clinic that administers the peptide, a potential financial interest.
Opinion has moved with regulatory events rather than new trials. Anti-doping authorities now prohibit it, and the US Food and Drug Administration (FDA) designated it a Category 2 substance in 2023 (significant safety concerns for compounding, meaning custom pharmacy preparation) before announcing its removal in April 2026 (law-firm summary). In July 2026 an advisory committee voted 8 to 6 (ABC News report) for compounding-list inclusion despite FDA staff concerns; ABC reports criticism that many newly appointed members have financial conflicts of interest. Critics cite missing human data; supporters cite consistent animal findings. Neither position is treated here as settled.
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High: no completed randomized controlled trial (a study that randomly assigns participants to treatment or inactive placebo) of BPC-157 in people has been published, and the human data are small uncontrolled series (patient reports with no comparison group).
Medium 🟩 🟩
No benefit reaches Medium: there is no single controlled human trial and no consistent observational dataset, only uncontrolled clinic case series.
Low 🟩
Knee Pain Relief
A clinic-run retrospective survey (looking back at existing records) of 16 patients given intra-articular (into the joint) BPC-157, alone or with a second peptide, found most reporting less pain. A systematic review counts it as the only clinical musculoskeletal study.
Magnitude: 14 of 16 patients (87.5%) reported relief, 11 of 12 with BPC-157 alone; with no control group or validated scale, the size of any true effect is unknown.
Interstitial Cystitis Symptom Relief ⭕️ Not Central to Health & Longevity
In a pilot study, 12 women with interstitial cystitis (a chronic painful bladder condition) unresponsive to an approved drug received one 10 mg BPC-157 injection around inflamed bladder tissue and all reported relief on a global questionnaire. It was uncontrolled and single-clinic. It bears on bladder disease, not general health.
Magnitude: 10 of 12 women reported complete symptom resolution and 2 of 12 about 80% resolution; no control group.
Speculative 🟨
Tendon, Ligament, Muscle, Bone & Wound Repair
In rats, BPC-157 improved healing after Achilles tendon transection (complete cut); a systematic review adds animal ligament, muscle and bone models. Basis is animal work, largely from one laboratory.
Gastrointestinal Lining Protection
A rat colitis study (colitis is bowel inflammation) reports gastrointestinal protection, matching the compound’s stomach-research origin. Human bowel-disease studies appear stopped without published conclusions, per USADA (no sales revenue); the basis is animal only.
Blood-Vessel & Reperfusion Protection
Rodent studies report less injury when blood flow returns after blockage (critical review), and human artery segments relaxed ex vivo (outside the body). The basis is animal and tissue work only.
Nervous-System Protection & Repair
Rat studies reported less hippocampal (memory-region) injury after temporary loss of blood flow, and faster recovery after sciatic nerve transection and spinal cord compression. Basis: animal work only; no human neurological outcomes exist.
Cardiac Protection
A review by the discovering group reports animal protection against myocardial infarction (heart attack), heart failure and rhythm disturbance. The basis is animal work from one laboratory; no human cardiac outcomes exist.
Liver Protection
In mice, oral BPC-157 reduced radiation-induced liver injury and liver-enzyme elevation in a preclinical study by an independent Taiwanese group. The basis is animal and cell work only; no human liver outcomes exist.
Pain & Inflammation Reduction
In rats, BPC-157 briefly raised the pain threshold after surgical incision and reduced inflammation and bone loss in experimental periodontitis (chronic gum disease). Basis: animal work only; no controlled human pain outcomes exist.
Longevity & Healthy-Aging Effects
No study has measured lifespan, years of healthy life or aging biomarkers for BPC-157 in any species. A 2026 gerontology review lists it among tissue-repair candidates on mechanistic grounds only.
Benefit-Modifying Factors
-
Genetic variants: No data link gene variants to response; because no principal receptor or metabolizing enzyme is identified, no variant is known to modify response.
-
Baseline biomarkers: No baseline biomarker has been tested as a predictor of response; published pilots selected patients by symptoms, not laboratory values.
-
Sex differences: No analysis by sex exists; the bladder pilot enrolled only women and the intravenous (into a vein) pilot one man and one woman.
-
Pre-existing conditions: All efficacy signals come from people with existing pain conditions; healthy adults have not been tested for any benefit. A narrative review proposes greater relevance in tissues with a poor blood supply, such as tendons, untested in people.
-
Age: Bladder pilot participants were aged 39–76 without age analysis; whether older adults heal or respond differently to BPC-157 is unknown.
-
Route and product: Response may differ by route (local versus systemic) and product purity; no study compares them, and reported benefits are anecdotal.
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: no controlled human study has documented adverse events for BPC-157, and the three published pilot series (knee, bladder and intravenous; about 30 people in total) reported none.
Medium 🟥 🟥
No risk reaches Medium: there is no single controlled human safety trial and no consistent observational safety dataset.
Low 🟥
Product Contamination & Mislabeling
Most products are unregulated “research use” powders, leaving identity, purity, sterility and dose unverified. Health Canada recalled unauthorized BPC-157 powder in May 2026, and a 2026 review lists contamination, impurities and inaccurate dosing as risks.
Magnitude: Direction only: the risk applies to products bought outside regulated pharmacy channels; the literature reports no outcome figure, such as a contamination rate.
Injection-Site & Systemic Reactions
The FDA received adverse event reports after BPC-157 injection, per RAPS coverage: nine days of injection-site redness and swelling, and shortness of breath needing an emergency visit. Causality is unclear, and a systematic review found no clinical safety data. Vendor materials also list nausea and dizziness.
Magnitude: Not quantified in available studies. Only isolated regulator-logged reports exist, and no controlled study has measured how often these reactions occur.
Speculative 🟨
Tumor or Abnormal Vessel Growth ⚠️ Conflicted
Blood-vessel-growth signaling raises a theoretical tumor concern; developers dispute it while reviewers maintain it. No test in cancer-bearing people exists. Net reading: unresolved, with neither harm nor safety demonstrated.
Immune Reactions
Regulators cite possible immune reactions (immunogenicity) to the peptide or impurities, per Examine’s summary of FDA statements. No human immunogenicity testing has been published; the basis is regulatory assessment only.
Blood Pressure & Nerve-Signaling Effects
Nitric oxide-mediated vessel relaxation in human artery segments and weak inhibition of an enzyme clearing a nerve messenger appear in laboratory studies. Effects on blood pressure or cognition in people are unmeasured.
Bleeding & Clotting Effects
A review of animal reports describes BPC-157 counteracting bleeding and thrombosis (clotting), so human effects are unknown; the registered hamstring trial (back-of-thigh muscle) excluded bleeding disorders and blood-thinner therapy. Basis: animal reports only.
Unknown Long-Term Safety
No human study exceeds a few weeks of dosing, and a systematic review found no clinical safety data. Long-term, pregnancy and pediatric effects are unmeasured; the basis is absent data.
Risk-Modifying Factors
-
Genetic variants: No data link gene variants to side effects; variants in blood-vessel-growth or nitric oxide pathways are theoretical modifiers only.
-
Baseline biomarkers: Liver and kidney function matter because a systematic review reports clearance through those organs; abnormal baseline values are untested as risk modifiers.
-
Sex differences: No sex-specific safety data exist; Examine states avoidance in pregnancy and lactation is warranted because data are absent.
-
Pre-existing conditions: Cancer history, blood-vessel-driven eye disease and bleeding or clotting disorders are theoretical risk modifiers; the registered hamstring trial excluded bleeding disorders and anticoagulant therapy (blood-thinning medication).
-
Age: Older adults carry more undetected tumors and vascular disease, theoretically raising concern about growth-promoting signals; no age-specific safety data exist.
Key Interactions & Contraindications
-
Prescription, anticoagulants and antiplatelets (blood thinners; warfarin, apixaban, clopidogrel): Caution. A review of animal reports describes BPC-157 counteracting bleeding and thrombosis (clotting), so human coagulation effects are unknown and bleeding or clotting risk is possible; excluded from the hamstring trial. Mitigation: prescriber review beforehand.
-
Prescription, blood pressure and nitrate drugs (vessel-relaxing medications; amlodipine, lisinopril, nitroglycerin): Monitor. Nitric oxide signaling could theoretically add to blood-pressure lowering, risking dizziness or fainting. Mitigation: home blood pressure readings after starting.
-
Prescription, VEGF-blocking drugs (cancer and eye medications; bevacizumab, ranibizumab, aflibercept): Avoid (theoretical). BPC-157 raises VEGF signaling that these drugs block, so either effect may be reduced. No mitigation established.
-
Prescription, cholinesterase inhibitors (dementia drugs; donepezil, rivastigmine, galantamine): Low-severity, theoretical. A 2026 laboratory study found only weak acetylcholinesterase inhibition (an enzyme clearing a nerve messenger); additive nausea or slow heart rate is unlikely but untested.
-
Over-the-counter, nonsteroidal anti-inflammatory drugs (NSAIDs, common pain relievers; ibuprofen, naproxen, aspirin): Severity none known. A review describes possible protection against NSAID gastrointestinal injury; human confirmation is absent. Aspirin adds to bleeding caution.
-
Supplement, other repair peptides (TB-500, GHK-Cu, a copper-binding peptide): Caution. Vendors sell them in blends with BPC-157; additive repair or growth signaling could theoretically compound the tumor and abnormal blood-vessel growth concern, and combined harms are unstudied.
-
Supplement, growth hormone-axis agents (somatropin, ipamorelin, CJC-1295, MK-677; drugs that trigger growth hormone release): Caution. BPC-157 raised growth hormone receptor expression in tendon cells, so additive growth signaling is theoretical, with a possible consequence of stronger growth-promoting effects on undetected tumors.
-
Supplement, nitric oxide boosters (L-arginine, L-citrulline, beetroot nitrate): Caution. In rats, BPC-157 effects were tested against L-NAME (a nitric oxide synthase blocker) and L-arginine; additive blood-pressure lowering in people is unstudied.
-
Other intervention, platelet-rich plasma (concentrated blood platelets) or corticosteroid (anti-inflammatory steroid; triamcinolone, methylprednisolone) injections: Severity unknown; monitor. Registered trials exclude recent platelet-rich plasma injection; additive healing signals or injection-site bleeding are theoretical and untested.
Populations who should avoid BPC-157:
- Pregnant or lactating people (no safety data; Examine states avoidance is warranted)
- Active cancer, cancer treated within the past 5 years, or an unevaluated suspicious lesion (theoretical growth-signaling concern)
- Eye disease driven by abnormal blood-vessel growth, such as wet macular degeneration (leaky new vessels causing central vision loss) or proliferative diabetic retinopathy (diabetic retinal vessel overgrowth), a theoretical concern
- Anticoagulant therapy or a known bleeding disorder (excluded from the registered hamstring trial)
- Age under 18 (excluded from all registered trials: hamstring, rotator cuff (shoulder tendon group), oral study)
- Severe uncontrolled cardiovascular, liver or kidney disease (excluded from the hamstring trial)
- Athletes in tested competition (prohibited at all times by anti-doping rules)
Risk Mitigation Strategies
-
Prescription-only sourcing: Product from a licensed pharmacy under prescription reduces contamination and wrong-dose risk compared with “research use” vials, though it does not prove purity.
-
Third-party batch testing: Lot-specific identity, purity (often 98% or higher by high-performance liquid chromatography, a purity-separation test) and endotoxin (bacterial toxin) results address contamination risk.
-
Sterile technique: Single-use needles, alcohol-swabbed vial stoppers and refrigerated storage after reconstitution (mixing powder with liquid) address the unverified-sterility contamination risk at injection sites.
-
Screening before use: Up-to-date age-appropriate cancer screening (colonoscopy, mammography) addresses the risk of promoting an unrecognized tumor.
-
Short defined courses: Typical reported courses last about 8 weeks with 8–10 weeks off, limiting exposure to unknown long-term risks.
-
One change at a time: Starting BPC-157 alone at 300–500 mcg (micrograms) per dose prevents misattributing an adverse event; blends obscure the cause.
-
Blood pressure self-monitoring: Home readings during the first weeks detect the theoretical blood-vessel-widening effect.
-
Observation after first dose: Watching for urticaria (hives), swelling or breathing difficulty after the first injection addresses immune-reaction risk.
-
Baseline and follow-up blood tests: Liver, kidney and glucose panels at baseline and course end detect effects on the organs that clear BPC-157, an unknown long-term safety concern.
Therapeutic Protocol
-
Common subcutaneous regimen: Huberman describes 300–500 mcg injected subcutaneously (under the skin) two or three times weekly for about 8 weeks, then 8–10 weeks off; this reflects reported practice, not trial-validated dosing.
-
Local versus systemic injection: Users inject near the injury or elsewhere subcutaneously; Huberman notes anecdotal reports that route matters little, and no study compares them.
-
Clinic-administered protocols: Published pilots used a single 10 mg bladder-wall injection, intra-articular knee injections and 10 mg then 20 mg intravenous infusions on consecutive days in two adults.
-
Oral tablets: A registered oral study gave 1 mg tablets, up to three tablets three times daily for 2 weeks, with results unpublished; Examine extrapolates about 110–180 µg per dose from rat data.
-
Competing approaches: Systemic injection, local injection, oral use and clinic-administered joint or bladder injection coexist without a comparative study or default.
-
Originators and popularizers: Predrag Sikiric’s Zagreb group developed the compound; Huberman popularized it and Attia critiques it; Florida clinician Edwin Lee authored the three human pilots (knee, bladder, intravenous).
-
Time of day: No study tests timing; registered trials use once-daily subcutaneous dosing for 14 days or 90 days without a specified hour.
-
Half-life: Plasma half-life is under 30 minutes in animals and, per a 2026 review, in a two-subject human pilot; no formal human pharmacokinetic study exists, and reported effects last hours to days, an unresolved mismatch.
-
Single versus split doses: Schedules range from a single session (bladder) to once daily (registered trials) to two or three times weekly; split dosing is untested.
-
Genetic variants: No data link gene variants to response, and no receptor or metabolizing enzyme is identified to guide dose choice.
-
Sex differences: No response or dosing data by sex exist.
-
Age considerations: Registered trials cap age at 45 (hamstring) or start at 18 (rotator cuff); pilots included ages 39–76 without age analysis, so dosing in older adults is unknown.
-
Baseline biomarkers: No biomarker guides dose or predicts response; the intravenous pilot tracked heart, liver, kidney, thyroid and glucose markers for safety only.
-
Pre-existing conditions: Registered trials exclude diabetes and autoimmune disease (rotator cuff) and bleeding disorders (hamstring); response in these groups is unstudied.
Discontinuation & Cycling
-
Duration: BPC-157 is used as short-term courses; no lifelong protocol has been studied, and registered trials run 14 to 90 days.
-
Withdrawal effects: None are reported in the three pilots (knee, bladder, intravenous) or registered protocols; dependence and rebound have not been studied.
-
Tapering: No taper is described; Huberman describes simply stopping at the end of a course.
-
Cycling: Reported practice is about 8 weeks on and 8–10 weeks off; Huberman cautions against indefinite daily use. No study tests whether cycling maintains efficacy.
-
Post-course tracking: Recording symptoms after stopping helps separate persistent effects from placebo (inactive-treatment) responses; no data define a normal pattern.
Sourcing and Quality
-
Legal supply: No approved product exists. Products are sold as “research use only” powders or made by 503A pharmacies (US rules for patient-specific compounded drugs); the FDA’s 2026 listing status remains unsettled (law-firm summary).
-
Forms: Free base (the unmodified peptide) and acetate (a salt form) are the forms considered by the advisory committee; vendors market an arginate salt (an arginine-based form) for oral stability (Grokipedia), and no independent comparison was found.
-
What to look for: Lot-specific certificates for identity, purity above 98% and endotoxin, ideally from an independent laboratory, plus sterile injectable preparation.
-
Reputable sources: No brand or pharmacy is endorsed here, and none has been independently verified. A 503A pharmacy supplied the bladder pilot’s product.
-
Storage: Grokipedia describes freeze-dried powder as stable short-term at room temperature and reconstituted solution as refrigerated and used within weeks.
Practical Considerations
-
Time to effect: No controlled time course exists; the registered hamstring trial checks imaging at day 14 and return to sport within 8 weeks, and reported benefits are anecdotal.
-
Common pitfalls: Concurrent use of several peptides, trusting unverified vials, treating testimonials as proof, and skipping rehabilitation, which every registered trial (hamstring, rotator cuff) pairs with treatment.
-
Regulatory status: Not FDA-approved; USADA states there is currently no legal basis to include it in compounded medication, and Health Canada recalled unauthorized powder. Neither agency earns revenue from the outcome.
-
Advisory vote: A July 2026 committee vote (ABC News report) is non-binding; ABC reports criticism that many newly appointed members have financial conflicts of interest.
-
Anti-doping: Prohibited at all times under the World Anti-Doping Agency’s non-approved substances category (USADA, which earns no revenue from BPC-157); a therapeutic use exemption is unlikely.
-
Cost and payers: Unapproved status means no established coverage. Payers favor lower-cost established options such as rehabilitation, a possible structural bias in guidelines and trial funding, while vendors and clinics profit from adoption.
Interaction with Foundational Habits
-
Sleep: Direction none established. No sleep study exists; theoretical nerve-signaling effects are laboratory-only. Timing relative to sleep is untested.
-
Nutrition: Direction none established. It resists stomach acid, and the registered oral study tested fasting and fed dosing; tissue repair depends on protein and micronutrients regardless of BPC-157.
-
Exercise: Direction potentiating, claimed but unproven. Registered trials pair it with standardized rehabilitation. Pain relief could allow overloading of healing tissue, a theoretical concern.
-
Stress management: Direction indirect at most. The discovering group frames the compound within a theory of stress coping and cytoprotection (protection of cells from damage), but no human cortisol or stress outcome exists.
Monitoring Protocol & Defining Success
Baseline testing before any use establishes a personal reference for liver, kidney, blood count, glucose, thyroid, inflammation and blood pressure, all values tracked in the published intravenous pilot or relevant to the reported clearance and vascular effects. No BPC-157-specific biomarker exists, so results are compared with the individual’s own baseline. Age-appropriate cancer screening status is also recorded. Repeat testing follows the timepoints below because registered trials run 14 to 90 days and clearance is reported through the liver and kidneys. Ongoing monitoring is described at baseline, at about 4 weeks, at the end of a course (about 8 weeks), and every 6–12 months while courses continue, with earlier testing for symptoms.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| ALT and AST | ≤ 25 U/L each | Liver safety | ALT (alanine aminotransferase) and AST (aspartate aminotransferase) are liver enzymes measured in units per liter (U/L). Conventional upper limits are about 40 U/L or higher. Fasting preferred. |
| eGFR and creatinine | eGFR ≥ 90 mL/min/1.73 m² | Kidney clearance | eGFR (estimated glomerular filtration rate) estimates kidney filtration; conventional threshold is ≥ 60. Avoid heavy exercise beforehand. |
| CBC | Platelets 150–350 ×10⁹/L | Bleeding and clotting baseline | CBC (complete blood count) covers red cells, white cells and platelets; conventional platelet range is the same. |
| Fasting glucose and HbA1c | Glucose 75–90 mg/dL; HbA1c ≤ 5.4% | Metabolic safety marker | HbA1c (glycated hemoglobin) reflects three-month average glucose. Conventional limits are < 100 mg/dL and < 5.7%. Fast 8–12 hours. |
| hs-CRP | < 1.0 mg/L | Inflammation baseline | hs-CRP (high-sensitivity C-reactive protein) is a general inflammation marker; conventional cutoff is < 3.0 mg/L. Avoid testing during illness. |
| TSH | 1.0–2.5 mIU/L | Thyroid safety marker | TSH (thyroid-stimulating hormone) is a standard thyroid marker; the intravenous pilot tracked thyroid markers. Conventional range is about 0.4–4.5 mIU/L. Morning draw preferred. |
| Blood pressure | < 120/80 mmHg | Theoretical blood-vessel widening | mmHg means millimeters of mercury; rest 5 minutes and average several home readings. Conventional normal is < 130/80. |
| Cancer screening status | No numeric target; track completion of age-appropriate screening | Growth-signaling concern | Colonoscopy, mammography or prostate-specific antigen testing per age and sex; results combine with imaging findings, not a single value. |
| Dilated eye exam (if retinal vascular disease) | No new abnormal vessel growth versus baseline | Vessel-growth concern | Relevant only with wet macular degeneration or proliferative retinopathy; compare with the ophthalmologist’s prior findings. |
Qualitative markers:
- Pain level and joint or tendon function (0–10 score versus own baseline)
- Sleep quality and energy
- Digestive comfort
- Dizziness or injection-site reactions
Emerging Research
-
Hamstring strain trial: NCT07437547 is a phase 2 (mid-stage test of effectiveness and dosing), industry-sponsored, placebo-controlled trial of 120 people with hamstring strain confirmed by magnetic resonance imaging (MRI, a detailed scan), given daily injections for 14 days; return-to-sport time and MRI injury volume are co-primary endpoints (the main outcomes measured). Recruiting in China.
-
Rotator cuff repair pilot: NCT07803250 is a phase 1 (early safety test) University of Arkansas trial of 30 people receiving daily injections for 90 days after rotator cuff repair, with shoulder strength as primary endpoint; not yet recruiting.
-
Oral safety study without results: NCT02637284 planned 42 healthy volunteers for oral dosing and pharmacokinetics; status unknown and results unposted, consistent with the note of stopped studies from USADA, which earns nothing from BPC-157.
-
Human pharmacokinetics and formulation: A 2026 review by Mateescu et al. identifies missing human pharmacokinetics as the main barrier, which could either support or weaken current dosing practice.
-
Replication of animal findings: A 2026 critical review by Demirtaş finds animal ischemia-reperfusion (injury when blood flow returns after blockage) evidence inconsistent and calls for independent blinded replication, which could strengthen or undermine the animal case.
-
Blood-vessel growth and tumor dispute: The developers’ defense (Sikiric et al., 2025) and the critics’ reply (Józwiak et al., 2025) frame toxicology and tumor-model studies as decisive either way.
-
Regulatory rulemaking: Following the advisory vote (ABC News report), FDA rulemaking would change access, not the evidence base.
Conclusion
BPC-157 is a laboratory-made chain of 15 amino acids that has drawn strong interest for tissue repair and general healthy aging. Its case rests almost entirely on animal and cell research, much of it from the group that discovered it, with little independent replication. Human evidence is limited to a few small clinic-run reports without control groups, so no benefit reaches even moderate confidence, and none has been tested for longevity itself. Reported risks are mostly theoretical or unmeasured: possible effects on new blood vessel growth, immune reactions, unknown long-term safety, and real uncertainty about what is actually in products sold outside regulated pharmacies. Drug regulators and sport authorities treat it as unapproved, and a recent advisory vote in favor of pharmacy preparation is non-binding. Financial interests touch the evidence on several sides: the discovering laboratory, clinics that administer it, vendors and pharmacies that sell it, and advisory members criticized for industry ties, while insurers and health systems favor established alternatives. Drug regulators and sport authorities have no sales revenue at stake. Nothing in these parties’ conclusions removes the uncertainty. For health- and longevity-focused adults willing to accept effort, cost and risk, the potential upside is plausible but unproven, and the downside is poorly characterized.